KHK inhibitor 2 is primarily utilized in research settings to study the role of the ketohexokinase (KHK) enzyme in metabolic pathways. It is particularly valuable in investigating conditions related to fructose metabolism, such as metabolic syndrome, obesity, and non-alcoholic fatty liver disease (NAFLD). By inhibiting KHK, this compound helps researchers understand the enzyme's impact on fructose-induced metabolic dysregulation. Additionally, it serves as a tool for exploring potential therapeutic strategies targeting fructose metabolism to mitigate associated health risks. Its application extends to preclinical studies aimed at developing treatments for diseases linked to excessive fructose consumption.